Photon-Counting Detector CT Enables Reduced Contrast Medium in Portal Venous Phase Imaging
Overview
This study demonstrates that photon-counting detector CT (PCD-CT) technology allows for a reduction in iodinated contrast medium volume from 120 mL to 100 mL during portal venous phase thoracoabdominal imaging without compromising image quality. Using 60 keV virtual monoenergetic imaging (VMI) further compensates for reduced iodine attenuation, maintaining diagnostic confidence compared to conventional energy-integrating detector CT (EID-CT).
Background
Contrast-enhanced thoracoabdominal CT is critical for oncologic patient evaluation but often involves high cumulative radiation and contrast medium (CM) doses, which carry risks such as post-contrast acute kidney injury and environmental concerns. The portal venous phase provides optimal visualization of tumors and lymph nodes, with image quality influenced by CM volume and iodine dose. Photon-counting detector CT (PCD-CT) technology enhances iodine contrast-to-noise ratio by better capturing low-energy x-ray photons, potentially enabling CM dose reduction while maintaining image quality.
Data Highlights
Parameter
PCD-CT 120 mL
PCD-CT 100 mL
EID-CT 120 mL
Contrast Medium Volume (mL)
120
100
120
Tube Voltage (kVp)
120
120 or 140
120
Image Quality Level
128 or 145
128 or 145
Not specified
Contrast-to-Noise Ratio (CNR)
High (reference)
Maintained with 60 keV VMI
Lower than PCD-CT
Patient BMI Range
18-30 kg/m²
18-30 kg/m²
18-30 kg/m²
Key Findings
PCD-CT with 100 mL contrast medium achieves comparable image quality and contrast enhancement to PCD-CT with 120 mL and EID-CT with 120 mL.
60 keV virtual monoenergetic imaging compensates for reduced iodine attenuation at lower CM volumes, improving contrast-to-noise ratio.
PCD-CT technology captures low-energy x-ray photons more efficiently than EID-CT, enhancing iodine contrast and reducing electronic noise.
Reducing CM volume from 120 mL to 100 mL in PCD-CT was driven by clinical workflow optimization and subjective radiologist impressions of over-enhancement at higher doses.
Exclusion of patients with BMI outside 18-30 kg/m² ensured consistency in CM dosing and image quality comparisons.
Clinical Implications
PCD-CT enables reduction of iodinated contrast medium volume during portal venous phase thoracoabdominal imaging without sacrificing diagnostic image quality, potentially lowering the risk of contrast-induced nephropathy and reducing environmental and economic burdens. Incorporation of 60 keV VMI reconstructions can further optimize image contrast when using reduced CM doses. These findings support updating clinical protocols to leverage PCD-CT technology for safer and more efficient oncologic imaging.
Conclusion
Photon-counting detector CT technology, combined with low-energy virtual monoenergetic imaging, allows for significant reduction in contrast medium volume during portal venous phase imaging while maintaining high image quality. This advancement may improve patient safety and resource utilization in oncologic CT imaging.
References
Various Authors/Clinical Trials Registration NCT04989192/2021-2023 -- Exploring the Role of Photon-Counting Detector CT Technology in Reducing Contrast Medium Use During Portal Venous Phase Thoracoabdominal Imaging
by Daniel Popp, Martin Siedlecki, Lena Friedrich, Mark Haerting, Christian Scheurig-Muenkler, Florian Schwarz, Thomas Kroencke, Stefanie Bette, Josua A. Decker
A large audit of biomedical publications suggests fabricated references are increasingly appearing in peer-reviewed papers — often in ways that are difficult for reviewers and readers to detect.
This quality improvement project found that using a distress screening tool for head and neck cancer patients who were 2 or more years post-treatment led to an increased number of referrals for psychosocial needs.
